COMPARISON

Melanotan II vs SS-31 (elamipretide)

2 attributes held for at least one of the two. 1 differ. Each value carries the register it came from and the date that register was read.

Answer

Melanotan II is authorised or registered in 0 and SS-31 (elamipretide) in 0 of the 10 registers read. Melanotan II: No trial states a phase. SS-31 (elamipretide): No trial states a phase. 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

Melanotan IISS-31 (elamipretide)
Registered trials
differs
26
clinicaltrials.gov · 2026-10-03
30
clinicaltrials.gov · 2026-10-03
EU authorisation
Nothing on record
ema read 2026-08-31
Nothing on record
ema read 2026-08-31

SIDE EFFECTS

Most common side effects, each beside its own placebo

Side effectMelanotan IIplaceboSS-31 (elamipretide)placebo
Injection site erythema--63.8%44.7%
Injection site pain--29.4%21.8%
Nasopharyngitis--5.5%2.4%
Nausea--4.8%4.7%
Headache--4.4%3.4%
Fall--4.3%4.7%
Hypertension--3.7%2.7%
Dizziness--3.1%2.5%
Cough--3.0%2.2%
Urinary Tract Infection--2.9%2.3%

Trial register Melanotan II: 0 placebo-controlled trials; SS-31 (elamipretide): 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Melanotan II side effects · SS-31 (elamipretide) side effects

LEGAL STATUS

Approval in each country read

CountryMelanotan IISS-31 (elamipretide)Register
United StatesNot on the registerNot on the registerRegulator FDA
European UnionNot on the registerNot on the registerRegulator EMA
United KingdomNot on the registerNot on the registerRegulator MHRA
CanadaNot on the registerNot on the registerRegulator Health Canada
AustraliaStatus unknownStatus unknown TGA
SwitzerlandNot on the registerNot on the registerRegulator Swissmedic
BrazilNot on the registerNot on the registerRegulator ANVISA
SerbiaNot on the registerNot on the registerRegulator ALIMS
SingaporeNot on the registerNot on the registerRegulator HSA
TurkeyNot on the registerNot on the registerRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.